FindTrial
Sign In

A real world study of Apatinib in the treatment of gynecological malignancies

A real world study of Apatinib in the treatment of gynecological malignancies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044858
Enrollment
Unknown
Registered
2021-03-30
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological Oncology

Interventions

single group:Non-intervention study

Sponsors

Shanxi Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged >= 18 years; 2.Gynecological malignancies diagnosed by pathology or histology; 3.Participate in the study voluntarily and sign the informed consent; 4.Researchers believe there are benefits.

Exclusion criteria

Exclusion criteria: 1.People who have been confirmed to be allergic to Apatinib mesylate tablets and/or their adjuvants; 2.Pregnant or lactating women; 3.Patients with Apatinib contraindications are excluded; 4.Persons deemed unsuitable for inclusion by doctors.

Design outcomes

Primary

MeasureTime frame
progression free survival;—

Countries

China

Contacts

Public ContactZhao Ruixia

Shanxi Cancer Hospital

458597129@qq.com+86 18360688809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026